Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stake Lessened by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC decreased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 6.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,222 shares of the pharmaceutical company’s stock after selling 5,128 shares during the period. Nisa Investment Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $28,278,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC grew its stake in shares of Vertex Pharmaceuticals by 5.8% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 598 shares of the pharmaceutical company’s stock worth $296,000 after purchasing an additional 33 shares during the last quarter. Public Sector Pension Investment Board boosted its holdings in Vertex Pharmaceuticals by 72.9% during the second quarter. Public Sector Pension Investment Board now owns 9,844 shares of the pharmaceutical company’s stock worth $4,614,000 after buying an additional 4,151 shares in the last quarter. Evergreen Capital Management LLC grew its position in Vertex Pharmaceuticals by 9.1% in the second quarter. Evergreen Capital Management LLC now owns 2,636 shares of the pharmaceutical company’s stock worth $1,236,000 after buying an additional 220 shares during the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its holdings in shares of Vertex Pharmaceuticals by 60.3% in the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 49,474 shares of the pharmaceutical company’s stock valued at $23,189,000 after buying an additional 18,605 shares in the last quarter. Finally, Sfmg LLC lifted its position in shares of Vertex Pharmaceuticals by 0.8% during the 2nd quarter. Sfmg LLC now owns 7,845 shares of the pharmaceutical company’s stock valued at $3,677,000 after acquiring an additional 60 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $428.00 on Thursday. The company’s 50 day moving average is $438.10 and its 200-day moving average is $465.39. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. The firm had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The business’s revenue was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.67 EPS. On average, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on VRTX. JPMorgan Chase & Co. cut their target price on Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating on the stock in a research report on Monday, December 23rd. Bank of America reduced their price objective on shares of Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a research note on Thursday, December 19th. Truist Financial dropped their target price on shares of Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating on the stock in a research report on Monday, December 23rd. Barclays reduced their price target on shares of Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating for the company in a research report on Friday, December 20th. Finally, Oppenheimer cut shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 19th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $490.38.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.